

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

INSIDE INFORMATION

LICENSE AGREEMENT WITH EQRX

This announcement is made by Hansoh Pharmaceutical Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the inside information provision (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on July 23, 2020 (before trading hours), Hansoh (Shanghai) Healthtech Co., Ltd. (翰森(上海)健康科技有限公司) and Jiangsu Hansoh Pharmaceutical Group Company Ltd. (江蘇豪森藥業集團有限公司) (collectively, the “**Licensors**”), each a wholly-owned subsidiary of the Group, entered into a strategic collaboration and license agreement (the “**License Agreement**”) with EQRx, INC. (“**EQRx**”), pursuant to which the Licensors grant, among others, an exclusive license to permit EQRx to research, develop, manufacture and commercialize Almonertinib and any product containing or comprising of Almonertinib in the field of treatment of cancer, cancer-related and immune-inflammatory diseases in humans outside of the People’s Republic of China (“**PRC**”). Almonertinib is one of our key products and has been granted drug registration approval for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with T790M mutation, who have progressed on or after EGFR-TKI therapy in PRC.

Pursuant to the License Agreement and subject to the terms and conditions thereof, Licensors are eligible to receive upfront and regulatory and development milestone payments of approximately US\$100 million, not including additional potential commercial milestone payments and tiered-royalties based on net sales. Such milestone payments are subject to achievement of relevant milestone events and are payable upon the first occurrence of the relevant milestone event. Under the License Agreement, EQRx is subject to customary exclusivity non-compete obligations, and the Licensors and EQRx are subject to customary mutual representations, warranties, covenants and indemnities.

EQRx is a bio-pharmaceutical company based in the United States which focuses on making innovative medicines at prices that are affordable for people and sustainable for society. EQRx is principally engaged in the business of innovative drug discovery, development and commercialization.

With EQRx's exceptional leadership team and extensive experiences in clinical development in the area of oncology therapeutics, it is expected that EQRx is well-positioned to accelerate the clinical development of Almonertinib outside of the PRC, and, if approved for marketing, will bring Almonertinib to more cancer patients in need around the world, and that the Group's collaboration with EQRx will further enhance our experience and infrastructure in connection with our clinical trial development and product commercialization. Accordingly, the Board believes that the License Agreement and the transactions contemplated thereunder are in the best interests of the Company and its shareholders as a whole.

To the best knowledge and belief of the Company, EQRx and its ultimate beneficial owner is independent of, and not connected with, the Company and its connected persons (as defined in the Listing Rules). The transactions contemplated under the License Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, July 23, 2020

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, Ms. Ma Cuifang as non-executive director, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.